Share Name Share Symbol Market Type Share ISIN Share Description
Polarean Imaging Plc LSE:POLX London Ordinary Share GB00BF3DT583 ORD GBP0.00037
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 48.00 420,718 08:00:22
Bid Price Offer Price High Price Low Price Open Price
47.00 49.00 48.60 48.00 48.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.74 -4.60 -4.30 78
Last Trade Time Trade Type Trade Size Trade Price Currency
17:11:03 O 43,500 47.997 GBX

Polarean Imaging (POLX) Latest News (3)

More Polarean Imaging News
Polarean Imaging Takeover Rumours

Polarean Imaging (POLX) Discussions and Chat

Polarean Imaging Forums and Chat

Date Time Title Posts
18/9/202009:25Polarean Imaging PLC471

Add a New Thread

Polarean Imaging (POLX) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Polarean Imaging trades in real-time

Polarean Imaging (POLX) Top Chat Posts

Polarean Imaging Daily Update: Polarean Imaging Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker POLX. The last closing price for Polarean Imaging was 48p.
Polarean Imaging Plc has a 4 week average price of 39p and a 12 week average price of 26.50p.
The 1 year high share price is 48.60p while the 1 year low share price is currently 15.50p.
There are currently 161,830,007 shares in issue and the average daily traded volume is 326,441 shares. The market capitalisation of Polarean Imaging Plc is £77,678,403.36.
hedgehog 100: It's interesting to compare POLX with AVCT, another COVID-19 play. Coincidentally, both raise funds at a placing price of 18p this spring, within a few weeks of each other: 13/03/2020 12:51 UK Regulatory (RNS & others) Polarean Imaging PLC Conditional Fundraise to raise GBP8.4 million "... GBP8.4 million (US$10.7 million) (before expenses) to be raised by means of a conditional fundraise (the "Fundraise") and the issue of, in aggregate 46,624,997 Fundraise Shares at 18 pence per Fundraise Share (the "Fundraise Price"). ..." 06/04/2020 07:00 UK Regulatory (RNS & others) Avacta Group PLC Proposed Placing to raise GBP3.75 million "...the Company has today conditionally raised gross proceeds of GBP3.75 million pursuant to a placing (the "Placing") through the issuance of 20,833,333 new ordinary shares ("Ordinary Shares") at a price of 18 pence per share, being the same price as the Subscription. ..." Since then AVCT has traded at over 200p per share, and is currently at 139p - a market cap. of £346M. Compared to POLX at 33p - a market cap. of a mere £54M. Although I would expect that to increase markedly this summer, with some key newsflow anticipated this quarter: • New orders to be announced shortly (currently being finalised). • FDA submission. • FDA expediated review news within 45 days of submission. And the closer we get to the FDA approval (effectively a licence to sell generally in the US), the more keenly will mass sales of POLX's technology be anticipated. From a December 2018 Northland Capital broker note on POLX: "“Polarean expects over US$500mln in system sales just to top-tier institutes,” said Alexandre in a note to clients."
hedgehog 100: 01/06/2020 07:00 UKREG Polarean Imaging PLC Appointment of Non-Executive Director "Polarean Imaging plc (AIM: POLX), a clinical stage medical imaging technology company developing a proprietary magnetic resonance imaging (MRI) drug-device combination, announces the appointment of Mr. Cyrille Petit to the Company's Board as a Non-Executive Director with immediate effect. Mr. Petit is Chief Corporate Development Officer and Head of Strategic Initiatives of the Bracco Group, a global leader in diagnostic imaging and medical devices ("Bracco"). Bracco recently acquired a 7.6% interest in the ordinary share capital of Polarean as part of the Company's GBP8.4m fundraise, which was first announced on 13 March 2020. As such, Cyrille Petit is joining the Board of Polarean as a representative of Bracco. Cyrille Petit began his career at Goldman Sachs and went on to specialise in external growth, mergers and acquisitions, and strategy at General Electric, where he worked for 15 years. In 2012, he joined the executive committee of Smith & Nephew PLC as Chief Corporate Development Officer, and later added the responsibilities of President, Global Business Services. There, he led the group's transformation and helped to accelerate growth through a series of transactions worth in excess of US$3B. ... Richard Hullihen, Chief Executive Officer o f Polarean, said: "Cyrille's direct experience is well matched to the markets and upcoming evolution of Polarean. He is welcome on the Board, and I am excited that he has agreed to join us in the Non-Executive Director role. On behalf of the Board, I would like to welcome Cyrille to Polarean and we look forward to the skills and advice he will bring to the Company." ..." As well as having a top role at Bracco, Cyrille Petit is also a director of Blue Earth Diagnostics, which was acquired by Bracco last year for $450M. I think there's a very good chance that history could repeat itself with POLX.
hedgehog 100: America is clearly a huge country: population 329 million, and growing rapidly, and with the world's largest economy. And America is also a vast and well-funded (multi-trillion dollar) healthcare market, which is at the forefront of applying new technology. In particular to POLX, America is at the forefront of investing into scanning capacity, especially compared to the UK. Which, combined with its huge size, shows what an important market it is for POLX. "Number of magnetic resonance imaging (MRI) units in selected countries as of 2017 (per million population) United States 37.56 Germany 34.49 …" HTTP:// "NHS must do more to future-proof its MRI capacity, say imaging experts Wednesday 10 May 2017 … The UK has 6.1 MRI systems per million people, fewer than countries including Estonia and Slovenia. …" HTTP:// "Number of computer tomography (CT) scanners in selected countries as of 2017 (per million population)  Australia 64.35 Iceland 44.33 United States 42.64 ..." HTTP:// "How does the NHS compare internationally? big election questions 02 June 2017 Authors Ruth Robertson ... The UK also has fewer CT scanners (8 per million population compared to an EU average of 21.4) and MRI scanners (6.1 per million compared to an EU average of 15.4) than most other European countries. However, this data does not include diagnostic scanners based in non-NHS providers that are used by the NHS. ... " HTTP:// As an American company, POLX looks particularly well-placed to exploit this huge market opportunity. And as the majority of POLX's sales are in US Dollars*, their sterling value will increase as sterling weakens against the Dollar, as it has been doing over the last several years. In addition, as a UK-listed company, a weaker sterling will also make a takeover of POLX cheaper for foreign predators, as they will get more sterling for their own currency. FDA-approval could potentially be a catalyst for such a takeover. * 27/06/2019 07:01 UK Regulatory (RNS & others) Polarean Imaging PLC Final Results "... The Group operates in Canada, Germany, the United Kingdom and the United States of America. Revenue by origin of geographical segment for all entities in the Group is as follows: Revenue 2018 2017 US$ US$ -------------------------- ---------- ---------- Canada 163,677 340,113 Germany 15,117 24,617 United Kingdom 38,661 111,765 United States of America 2,221,684 760,668 -------------------------- ---------- ---------- Total 2,439,139 1,237,163 ..." GBPUSD Chart
hedgehog 100: Hedgehog 100 16 May '20 - 19:27 - 394 of 398 Edit 0 4 0 " ... In addition, you tend to find that a share price will appreciate a lot during the FDA approval process, in anticipation of the approval. ..." A good relatively recent example is Shield Therapeutics (STX). STX rose about six-fold in the first seven months of last year, from about 30p, until just after its FDA approval on 26th. July 2019. And it more than trebled during this period ahead of the FDA approval, before enjoying a very strong rise at the FDA approval itself. 26/07/2019 07:00 UKREG Shield Therapeutics PLC FDA approves Feraccru® with a broad label "London, UK, 26 July 2019: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency, announces that the U.S. Food and Drug Administration (FDA) has approved its lead product Feraccru(R) / Accrufer(R) for the treatment of iron deficiency in adults. With this broad label approval Accrufer(R) (as the product will be marketed in the USA) has taken a big step towards exploiting the very large commercial opportunity in the USA, the world's largest and most attractively reimbursed pharmaceutical market. Market research suggests that the prescription market for iron replacement therapy in the USA is worth over $1.0bn annually. There are between 8 million and 9 million patients in the USA who suffer from iron deficiency anaemia and management estimate potentially two to three times this number require treatment for iron deficiency. ..."
hedgehog 100: Also, there's a lot of potential near-term positive newsflow in the pipeline in addition to the FDA approval process. Thanks to diversification for this excellent summary: diversification 28 Apr '20 - 15:39 - 358 of 394 0 3 0 "News pending (IMO) Today 10:17 - Sale of additional Polarizers (min 3) - Read out from AstraZeneca Phase 3 study - Bracco Imaging international expansion/approval - Big Pharma collab - Potential scientific user application related to COVID19 - Pre-NDA meeting imminent - NDA submission With the share price at 24p we are at a pivotal point. If we breakout today (L2 1v3) with more volume, this tightly held stock could head back towards its ATH with plenty of justification. Fully funded through to FDA approval their will be plenty of newsflow, some of which I haven’t even mentioned, and with a £40m market cap their isn’t a sector I would rather be in than pulmonary imaging right now!"
hedgehog 100: RichardJohn1014 May '20 - 18:16 - 390 of 393 0 1 1 "FDA is a year away so why are you investing now? I’m just curious?" Richard, In a sector where it can take a decade or more to bring a drug to market, a year will be regarded as pretty close by most investors. And it could potentially be a lot sooner than a year: say 6 months or so for a priority review ... and even faster than that if it's fast-tracked for the COVID-19 benefit. In addition, you tend to find that a share price will appreciate a lot during the FDA approval process, in anticipation of the approval. And remember that with its recent fundraising POLX is fully-funded for the FDA approval process ... and that there's not the same real risk of rejection as with drugs, where there can be unpleasant side effects. "Priority review From Wikipedia, the free encyclopedia Priority review is a program of the United States Food and Drug Administration (FDA) to expedite the review process for drugs that are expected to have a particularly great impact on the treatment of a disease. ..." "Fast track (FDA) From Wikipedia, the free encyclopedia Fast track is a designation by the United States Food and Drug Administration (FDA) of an investigational drug for expedited review to facilitate development of drugs which treat a serious or life-threatening condition and fill an unmet medical need. Fast Track designation must be requested by the drug company. The request can be initiated at any time during the drug development process. FDA will review the request and attempt to make a decision within sixty days. ..."
diversification: I hope these scientific collaborations bear fruit. Any announcement on how our IP can assist on the diagnostics or pulmonary function concerning COVID19 will set a fire underneath the share price. I see they are using virtual reality: Well surely a scan accessing the improvement or deterioration of lung function with over 300 drug trials taking place concerning the improvement of pulmonary function is a good enough justification to include POLX while throwing the kitchen sink at it! I think the Pre NDA meeting is next week from what was said in a recent interview where they discuss the possibility of fast track, let alone priority review. Lung damage to those that have had COVID19 needs to be addressed at an early stage with ongoing treatments stunting deterioration ASAP. Our time is coming, I am convinced if it.
gregb: Fund raise shares to be admitted to the register tomorrow subject to today's vote. Anyone have a view on how this will affect the share price? I take it the placing price of 18p should underpin it.
diversification: Share register rebalanced Fantastic results today, and while these results were expected the main news today is that the market seems to of filtered out some of the traders and profit takers which was really good to see. Too much hot money is not necessarily a good thing, a sustainable long term uptrend is far more appealing. Funding Recent director purchases would have provided a base to the current share price, as for Allis to have continued to build a sizable position in the company knowing the companies forward cash position, surely if a sizable placing was planned he could of just participated in that. It is also worth noting that the CEO has insisted in the past that the company cash burn is very little following the expensive phase III trial which should see the company through to approval. Strategic partnerships Today’s read out is a key milestone for the company to enable it to enter strategic partnerships which in itself would resolve any funding concerns. NDA Monday this week I contacted investor relations to help clarify priority FDA reviews and Hatch Waxman. I am waiting a response as it was implied that Richard was very busy this week and it may take a couple of days to reply. Conclusion (in my opinion) Imo something significant is being worked on in the background that has led the company directors to build on their own position in the free market. Allis will be only to aware of the potential of this company following the sale of Blue Earth D which means that he has unfinished business in building a more significant stake in POLX. Relatively low forward cash burn enables the company to go into the next 18 months with a relatively clear path to market which can give current shareholders certainty about forward dilution. To consider a small raise would not be the end of the world but I think the company will naturally clarify its forward position in the not to distant future. NDA application, strategic partnerships and further sale of goods for research purposes (funding through grants, which enables the company to have a clear view of forward order book), will all contribute towards future funding and will be significant share price catalysts as it’s the unknowns that the market will struggle to price in. Between now and FDA approval, the free float will continue to shrink which will intensify and future forward moves. I have seen many stocks that have seen a continuation of an upwards trend in anticipation of FDA approval over a longer period of time (STX) and also over a shorter period of time just before FDA results. I see no reason for this to be any different, other than the fact that this is a computer v computer which will help increase the probability of success. None of which is currently priced in, but prior to what could/should be FDA approval and commercialization would see a market cap in excess of £100m which in itself is a share price of 87p or a 170% increase on today’s price which would be more than conservative knowing the commercial numbers, even for a pre-approved application at this stage of its lifecycle.
kj kelley: Amphion's may not have the luxury of selling into the news. Loan favility is due to be repaid on 30th September 2019. It has pledged it's Polarean shareholding against this debt. It is trying to refinance or extend this debt. As the debt is effectively to allow Amphion to speculate on the price of POLX shares, I would be surprised if lenders would provide more funds to Amphion, especially in the current financial climate. The debt outstanding is $2.8m against which POLX shares are pledged. The value of the POLX shares was $5.3m on 9th August and is now worth $4.8m. Of this $4.8m the lenders are entitled to 15% of the aprreciation above 18p share price of POLX, whcih is around $0.2m currently. So we might see the lender acquiring POLX shares in repayment of the debt and these shares being sold. Amphion has a market cap of £0.3m and the company's total debt is $30.3m. It's accounts have not been published as the auditors are continuing work in relation to the going concern status of the company. It seems that Amphion is very close to being declared bust. If so this will create a substantial overhang in Polarean's shares. This years placing at 18p showed that there was demand for the shares at that price. Althought market conditions have chnaged since then.
Polarean Imaging share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Polarean I..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200920 02:24:19